Cargando…
Humoral response to mRNA‐based COVID‐19 vaccine in patients with myeloid malignancies
Data on the response to the COVID‐19 vaccine in patients with myeloid malignancy, who are at severe risk in case of infection, have not emerged. In a study of 69 patients with myeloid malignancies, including 46 patients with acute myeloid leukaemia (AML) and 23 patients with myelodysplastic syndrome...
Autores principales: | Mori, Akio, Onozawa, Masahiro, Tsukamoto, Shihori, Ishio, Takashi, Yokoyama, Emi, Izumiyama, Koh, Saito, Makoto, Muraki, Haruna, Morioka, Masanobu, Teshima, Takanori, Kondo, Takeshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111452/ https://www.ncbi.nlm.nih.gov/pubmed/35226358 http://dx.doi.org/10.1111/bjh.18138 |
Ejemplares similares
-
Humoral response to mRNA‐based COVID‐19 vaccine in patients with de novo and pre‐existing immune thrombocytopenia with exacerbation of thrombocytopenia after vaccination
por: Mori, Akio, et al.
Publicado: (2022) -
Humoral response to mRNA‐based COVID‐19 vaccine in patients with immune thrombocytopenia
por: Mori, Akio, et al.
Publicado: (2022) -
Booster Effect of a Third mRNA-Based COVID-19 Vaccine Dose in Patients with Myeloid Malignancies
por: Mori, Akio, et al.
Publicado: (2022) -
Humoral response to mRNA-based COVID-19 vaccine and booster effect of a third dose in patients with mature T cell and NK-cell neoplasms
por: Kobayashi, Mirei, et al.
Publicado: (2023) -
Booster effect of a third mRNA‐based COVID‐19 vaccine dose in patients with myeloid malignancies
por: Mori, Akio, et al.
Publicado: (2023)